Medical Developments International Limited announced that it has discontinued the preparation of clinical trials for Penthrox in China. This follows extended delays to the anticipated timeline for clinical trial outcomes and consequently the commercial launch of Penthrox in the market, primarily due to the challenging regulatory environment and COVID restrictions.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.44 AUD | -2.22% | -2.22% | -42.11% |
29/04 | Transcript : Medical Developments International Limited, Q3 2024 Earnings Call, Apr 29, 2024 | |
29/02 | Transcript : Medical Developments International Limited, H1 2024 Earnings Call, Feb 29, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.11% | 25.53M | |
+32.95% | 698B | |
+26.51% | 568B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+15.70% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B |
- Stock Market
- Equities
- MVP Stock
- News Medical Developments International Limited
- Medical Developments International Limited Discontinues China Clinical Trials